Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 15/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21241503 | 1.00 | FKBP1A (0.61) | FKBP1AALDH1A1TP53MEN1KMT2A | |
| SCHEMBL21241498 | 0.94 | FKBP1A (0.69) | FKBP1A | |
| SCHEMBL21241599 | 0.94 | FKBP1A (0.69) | FKBP1A | |
| SCHEMBL21241496 | 0.92 | FKBP1A (0.65) | FKBP1AALDH1A1TP53MEN1KMT2A | |
| SCHEMBL21241597 | 0.92 | FKBP1A (0.65) | FKBP1AALDH1A1TP53MEN1KMT2A | |
| SCHEMBL21241274 | 0.92 | FKBP1A (0.65) | FKBP1AALDH1A1TP53MEN1KMT2A | |
| SCHEMBL22861564 | 0.92 | FKBP1A (0.65) | FKBP1AALDH1A1TP53MEN1KMT2A | |
| SCHEMBL25756833 | 0.84 | FKBP1A (0.60) | FKBP1AALDH1A1 | |
| SCHEMBL21241272 | 0.84 | FKBP1A (0.61) | FKBP1ANPSR1 | |
| SCHEMBL21241277 | 0.84 | FKBP1A (0.61) | FKBP1ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3746440-B1 | PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME | UNIV TEXAS (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11345659-B2 | Pipecolic esters for inhibition of the proteasome | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-31 | — | — | US | disclosed |
| US-11345659-B2 | Pipecolic esters for inhibition of the proteasome | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210002220-A1 | PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2021-01-07 | — | — | US | disclosed |
| WO-2019152527-A1 | PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345659-B2 | Pipecolic esters for inhibition of the proteasome | PSMG3, PSME3, PSMC1 | FKBP1A 1719/4885ALDH1A1 4172/4885TP53 90/4885 |
| US-20210002220-A1 | PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME | PSMG3, PSME3, PSMC1 | FKBP1A 1719/4885ALDH1A1 4172/4885TP53 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.